In this study, CB-CAPs and AVISE Lupus were used to examine patients suspected of #lupus to determine if they could predict the transition to classifiable SLE. Click here to learn more. #rheumatology #autoimmunedisease #immunology #autoimmuneresearch https://lnkd.in/gg99k-M4
Exagen Inc.
Biotechnology Research
Vista, California 6,749 followers
A patient focused, discovery driven life science company.
About us
Exagen Inc. is a Patient Focused, Discovery Driven, CLIA-certified, CAP-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of Rheumatology and Autoimmune diseases. Committed to Personalized Medicine, our AVISE tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. For more information on our company, please visit www.Exagen.com. For more information on AVISE testing services, please visit www.AviseTest.com. Read our Social Media Terms of Use here: http://bit.ly/smtou
- Website
-
http://www.Exagen.com
External link for Exagen Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Vista, California
- Type
- Public Company
- Founded
- 2002
- Specialties
- Diagnostic Testing, Prognostic Testing, Therapeutic Drug Monitoring, and Biotech
Locations
-
Primary
Get directions
1261 Liberty Way
Vista, California 92081, US
Employees at Exagen Inc.
Updates
-
Learn how #AVISE Lupus increases physician confidence in SLE treatment decisions. #autoimmunedisease #immunology #autoimmuneresearch #lupus #rheumatology https://ow.ly/1OKi50UmuvY
-
-
Exagen is excited to announce that we have reached a significant milestone— completing our 1 millionth AVISE CTD test. We are proud to support patients and clinicians with the information they need to manage connective tissue diseases. https://lnkd.in/gPWTVNkJ #autoimmune #AVISE
-
-
Our webinar is right around the corner. Don’t miss this opportunity to learn about novel biomarkers with the potential to transform #lupus and #rheumatoidarthritis patient care. https://lnkd.in/gd9M7gEA
-
Seronegative and seropositive #rheumatoidarthritis patients have different risk factors, pathologic features, and medication responses. Register for our webinar to learn more. #autoimmunedisease #rheumatology https://ow.ly/HiRW50UlXjC
-
-
How can we accelerate the diagnosis journey for #lupus patients? Join us for our webinar to learn more. #autoimmunedisease #rheumatology https://ow.ly/Wl2m50UmuKg
-
-
If you are interested in learning more about the role of anti-RA33 autoantibodies in immune response, join us at our upcoming webinar. #rheumatology #autoimmunedisease #rheumatoidarthritis #lupus https://ow.ly/1RgH50UjipO
-
-
Evaluating their unique signature in #autoimmunedisease can improve diagnostic accuracy when testing suspected #lupus patients. https://ow.ly/rWpB50Ub94W
-
-
Register for our webinar to learn more about how anti-RA33 autoantibodies are improving test accuracy for seronegative #rheumatoidarthritis patients. #autoimmunedisease #rheumatology https://ow.ly/aJW750UaxNP
-
-
Join us for an insightful live session on how emergent biomarkers are transforming the diagnosis of #lupus and #rheumatoidarthritis. Register today! https://ow.ly/YjcA50UaxFy #autoimmunedisease #rheumatology
-